Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (the "Company") on December 10, 2018, reporting events occurring on December 4, 2018. The Company is an emerging growth company incorporated in Delaware. The filing concerns the termination of a material definitive agreement involving Napo Pharmaceuticals, Inc., a wholly-owned subsidiary of the Company.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data for the reporting period. The only specific financial figure disclosed is a one-time lump sum "Buyout Fee" of $250,000 payable to SmartPharma, LLC to effectuate the termination of their alliance. The Company guarantees all payment obligations under the termination agreement.
Material Changes
On December 4, 2018, Napo Pharmaceuticals, Inc. and SmartPharma, LLC entered into a Suspension, Settlement and Termination Agreement to end their Strategic Marketing Alliance Agreement dated April 4, 2016. Key changes include:
- Suspension: The Alliance Agreement was suspended retroactively as of October 31, 2018.
- Termination Condition: The agreement will automatically terminate upon the Company's payment of the October 2018 sales commission and the $250,000 Buyout Fee.
- Reinstatement Risk: If the Buyout Fee is not paid by January 8, 2019, the Alliance Agreement will be reinstated. Under reinstatement, SmartPharma would no longer perform marketing services, but the Company would remain obligated to pay remuneration based on net sales until October 2021.
- Strategic Driver: The termination follows the appointment of Robert J. Griffing as the chief commercialization officer of Napo.
Outlook, Risks, and Management Commentary
The Company intends to assume direct control over the commercialization of Mytesi, its FDA-approved anti-secretory agent for noninfectious diarrhea in adults with HIV/AIDS, following the termination of SmartPharma's marketing services. A primary contingency is the January 8, 2019 deadline for the Buyout Fee payment; failure to meet this deadline results in a reinstated agreement where the Company continues to pay royalties without receiving marketing services.
Investor Verification Checklist
- Confirm whether the $250,000 Buyout Fee was paid by the January 8, 2019 deadline to ensure the Alliance Agreement was fully terminated.
- Verify the impact of the new commercialization strategy under Robert J. Griffing on future sales of Mytesi.
- Review the full text of the Suspension, Settlement and Termination Agreement (Exhibit 10.1) for any additional covenants or liabilities.
- Monitor subsequent filings for any reinstatement of the Alliance Agreement or disputes regarding the October 2018 payment.